These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 35784713)
1. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5. Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713 [TBL] [Abstract][Full Text] [Related]
2. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5. Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564 [TBL] [Abstract][Full Text] [Related]
3. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Peyrin-Biroulet L; Christopher R; Behan D; Lassen C Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838 [TBL] [Abstract][Full Text] [Related]
4. P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis. Long M; Cross R; Calkwood J; Pondel M; Pai A; Ahmad H; Charles L; Elegbe A; Petersen A; Sheffield J; Javed A; Wolf D Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9-S10. PubMed ID: 37461957 [TBL] [Abstract][Full Text] [Related]
5. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors. Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447 [TBL] [Abstract][Full Text] [Related]
6. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity. Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079 [TBL] [Abstract][Full Text] [Related]
7. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Rowan C; Ungaro R; Mehandru S; Colombel JF Expert Opin Pharmacother; 2022 Jun; 23(8):893-904. PubMed ID: 35503955 [TBL] [Abstract][Full Text] [Related]
9. P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial. Colombel JF; D'Haens G; Irving P; Petersen A; Chitkara D; Marta C; Chen T; Charles L; Danese S; Ghosh S Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S9. PubMed ID: 37461956 [TBL] [Abstract][Full Text] [Related]
10. Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis. Chiba K; Adachi K Pharmaceuticals (Basel); 2012 May; 5(5):514-28. PubMed ID: 24281561 [TBL] [Abstract][Full Text] [Related]
11. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data. Schoedel KA; Kolly C; Gardin A; Neelakantham S; Shakeri-Nejad K Psychopharmacology (Berl); 2022 Jan; 239(1):1-13. PubMed ID: 34773483 [TBL] [Abstract][Full Text] [Related]
12. Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects. Lassiter G; Melancon C; Rooney T; Murat AM; Kaye JS; Kaye AM; Kaye RJ; Cornett EM; Kaye AD; Shah RJ; Viswanath O; Urits I Neurol Int; 2020 Dec; 12(3):89-108. PubMed ID: 33287177 [TBL] [Abstract][Full Text] [Related]
13. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275 [TBL] [Abstract][Full Text] [Related]
15. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis. Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G Cells; 2020 May; 9(5):. PubMed ID: 32455907 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis. Bencardino S; D'Amico F; Faggiani I; Bernardi F; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568417 [TBL] [Abstract][Full Text] [Related]
17. The Current Landscape in the Development of Small-molecule Modulators Targeting Sphingosine-1-phosphate Receptors to Treat Neurodegenerative Diseases. Sankar Kar S; Gharai SR; Sahu SK; Ravichandiran V; Swain SP Curr Top Med Chem; 2024 Apr; ():. PubMed ID: 38676503 [TBL] [Abstract][Full Text] [Related]
18. S1P signaling: new therapies and opportunities. Gonzalez-Cabrera PJ; Brown S; Studer SM; Rosen H F1000Prime Rep; 2014; 6():109. PubMed ID: 25580263 [TBL] [Abstract][Full Text] [Related]
19. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Brinkmann V Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729 [TBL] [Abstract][Full Text] [Related]
20. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Aoun R; Hanauer S Expert Rev Gastroenterol Hepatol; 2022 May; 16(5):411-423. PubMed ID: 35400292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]